First In Ventures — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Gliknikgliknik.comJun 2023
Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
BiotechBaltimore, US
David S. Block(Executive Officer, Director)Elizabeth C. Block(Executive Officer)Raymond Shinazi(Director)Joseph Klein(Director)Elizabeth Block(Executive Officer)Mark Lerner(Director)
Board seatKyle Rusconi· per SEC Form D
Co-investorsBrace Pharma
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.